Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Cellectis S.A. for the month of November 2025. The filing, dated November 3, 2025, serves primarily to distribute a press release (Exhibit 99.1) to U.S. investors. The registrant is headquartered in Paris, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a comprehensive financial statement.
Material Changes
No material financial changes versus prior periods are detailed in the provided text. The content is limited to the cover page and exhibit index referencing a press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risk factors, or details on contingencies and unusual items. These details are presumably contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Key Facts for Investor Verification
- Verify the content of the press release dated November 3, 2025 (Exhibit 99.1) for specific operational or clinical updates.
- Confirm the company's current cash position and runway by reviewing the most recent Form 20-F or quarterly reports, as this 6-K contains no financial data.
- Note that the filing was signed by André Choulika, Chief Executive Officer.